Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines-Reference-Cited by-同舟云学术

Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines

Published:2012-08 Issue:8 Volume:48 Page:678-685
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Tano Tomoyuki,Okamoto Masato,Kan Shin,Nakashiro Koh-ichi,Shimodaira Shigetaka,Yamashita Naomi,Kawakami Yutaka,Hamakawa Hiroyuki

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference41 articles.

1. Studies on the anticancer and stretolysin S-forming abilities of hemolytic streptococci;Okamoto;Jpn J Microbiol,1967

2. New approach to management of malignant ascities with a streptococcus preparation, OK-432. Improvement of host immunity and prolongation of survival;Torisu;Surgery,1983

3. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer;Watanebe;J Biol Response Mod,1987

4. Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma;Kikkawa;Eur J Cancer,1993

5. Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion;Maehara;Am J Surg,1994

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei;Cancer Biology & Medicine;2024-07-18

2. Immunoexpression pattern of TLR3 and TLR7 in minor salivary gland adenoid cystic carcinoma and its role in prognosis;Cancer Treatment and Research Communications;2024

3. Cudraflavone B induces human glioblastoma cells apoptosis via ER stress-induced autophagy;BMC Neuroscience;2023-01-31

4. MD2 Is a Potential Biomarker Associated with Immune Cell Infiltration in Gliomas;Frontiers in Oncology;2022-03-17

5. TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings;Molecular Pharmaceutics;2018-09-18